Home
Clinical Resources Search
PQI: Sacituzumab govitecan (Trodelvy®): Management of Neutropenia and Diarrhea

Sacituzumab govitecan (Trodelvy®): Management of Neutropenia and Diarrhea

Download PQI pdf 0.28MB

Last Updated: May 21, 2024

By: Rebecca Martin, PharmD, BCOP

About this PQI

Sacituzumab govitecan-hziy is an antibody drug conjugate (ADC) that is indicated in triple negative as well as hormone receptor positive, HER2 negative [HR(+) HER2(-)] breast cancer.1-3 The purpose of this PQI is to provide information on the management of common adverse events including diarrhea and neutropenia, as well as prophylaxis of nausea and vomiting.

More About This PQI

PQI in Action Articles:

Sacituzumab_trodelvy_Diarrhea pdf 1.55MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Breast Cancer Urothelial Carcinoma Sacituzumab govitecan Trodelvy

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Sacituzumab govitecan (Trodelvy®): Management of Neutropenia and Diarrhea

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Tucatinib (Tukysa®) Management

PQI: The Role of Pharmacy in Equitable Breast Cancer Care

PQI: Stomatitis Prophylaxis During Everolimus (Afinitor®) Therapy

PQI: Overview of Breast Cancer Survivorship

PQI Podcast S6 Ep 7: Urology Clinic Best Practices

PQI: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI: Enfortumab Vedotin-ejfv (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma

PQI in Action: Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma – 2

PQI in Action: Sacituzumab Govitecan (Trodelvy®): Management of Neutropenia and Diarrhea

PQI in Action: Sacituzumab Govitecan (Trodelvy®): Management of Neutropenia and Diarrhea

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings